[HTML][HTML] Dealing with conflicts of interest
AS Relman - New England Journal of Medicine, 1984 - Mass Medical Soc
AS Relman
New England Journal of Medicine, 1984•Mass Medical SocConnections between industry and academic medical scientists are not new. It has long
been common practice for manufacturers of pharmaceuticals and medical devices to retain
the services of academic scientists as consultants or to subsidize their research studies—
particularly clinical trials of marketable products in which the company is interested. But in
recent years, as the commercial possibilities of new biomedical discoveries have become
increasingly attractive, these connections have become more pervasive, complex, and …
been common practice for manufacturers of pharmaceuticals and medical devices to retain
the services of academic scientists as consultants or to subsidize their research studies—
particularly clinical trials of marketable products in which the company is interested. But in
recent years, as the commercial possibilities of new biomedical discoveries have become
increasingly attractive, these connections have become more pervasive, complex, and …
Connections between industry and academic medical scientists are not new. It has long been common practice for manufacturers of pharmaceuticals and medical devices to retain the services of academic scientists as consultants or to subsidize their research studies — particularly clinical trials of marketable products in which the company is interested. But in recent years, as the commercial possibilities of new biomedical discoveries have become increasingly attractive, these connections have become more pervasive, complex, and problematic.
Now, it is not only possible for medical investigators to have their research subsidized by businesses whose products they are studying, or act as . . .
The New England Journal Of Medicine